Gene expression and polymorphisms of DNA repair enzymes:: Cancer susceptibility and response to chemotherapy

被引:25
作者
Camps, Carlos
Sirera, Rafael
Iranzo, Vega
Taron, Miquel
Rosell, Rafael
机构
[1] Hosp Gen Univ Valencia, Med Oncol Serv, Valencia 46014, Spain
[2] Hosp Gen Univ Valencia, Fdn Invest, Oncol Mol Lab, Valencia 46014, Spain
[3] Hosp Univ Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain
关键词
cisplatin; single nucleotide polymorphisms; squamous cell carcinoma;
D O I
10.3816/CLC.2007.n.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Platinum compounds play a central role in cancer chemotherapy. Although treatment is limited by side effects, they continue to have widespread application. One of the main aims of clinical or translational research in cancer is the search for genetic factors that could foresee treatment outcomes, in biologic activity and toxic effects. This genetic analysis might allow selection of patients who will have the greatest benefit from chemotherapy. Furthermore, a better knowledge of the underlying molecular profile of the host and the tumor will facilitate screening for lung cancer susceptibility and tailoring of chemotherapy in individual patients, choosing those most likely to respond, adjusting doses more precisely in order to reduce less adverse effects, and establishing safety profiles based on individual genetic analyses. Herein, we discuss current knowledge regarding gene expression and polymorphisms of DNA repair enzymes in regard to cancer susceptibility and response to chemotherapy.
引用
收藏
页码:369 / 375
页数:7
相关论文
共 94 条
[1]  
Balaña C, 2003, CLIN CANCER RES, V9, P1461
[2]   Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2 [J].
Beiner, Mario E. ;
Rosen, Barry ;
Fyles, Anthony ;
Harley, Ian ;
Pal, Tuya ;
Siminovitch, Kathy ;
Zhang, Shiyu ;
Sun, Ping ;
Narod, Steven A. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (09) :1636-1640
[3]   Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].
Bellmunt, J. ;
Paz-Ares, L. ;
Cuello, M. ;
Cecere, F. L. ;
Albiol, S. ;
Guillem, V. ;
Gallardo, E. ;
Carles, J. ;
Mendez, P. ;
de la Cruz, J. J. ;
Taron, M. ;
Rosell, R. ;
Baselga, J. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :522-528
[4]   Markers of DNA repair and susceptibility to cancer in humans: An epidemiologic review [J].
Berwick, M ;
Vineis, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) :874-897
[5]  
Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091
[6]   Genetic polymorphisms in DNA repair genes and risk of lung cancer [J].
Butkiewicz, D ;
Rusin, M ;
Enewold, L ;
Shields, PG ;
Chorazy, M ;
Harris, CC .
CARCINOGENESIS, 2001, 22 (04) :593-597
[7]  
Camps Carlos, 2003, Clin Lung Cancer, V4, P237, DOI 10.3816/CLC.2003.n.004
[8]   DNA repair: Enzymatic mechanisms and relevance to drug response [J].
Chaney, SG ;
Sancar, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (19) :1346-1360
[9]   DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population [J].
Chen, SQ ;
Tang, DL ;
Xue, KX ;
Xu, L ;
Ma, GJ ;
Hsu, YZ ;
Cho, SS .
CARCINOGENESIS, 2002, 23 (08) :1321-1325
[10]   Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis [J].
Cheng, L ;
Spitz, MR ;
Hong, WK ;
Wei, QY .
CARCINOGENESIS, 2000, 21 (08) :1527-1530